Get Premium to unlock powerful stock data
NAS:NKTR (USA)  
Nektar Therapeutics logo

Nektar Therapeutics

$ 3.75 -0.05 (-1.32%) 08:08 PM EST
P/E:
At Loss
P/B:
1.15
Market Cap:
$ 698.53M
Enterprise V:
$ 173.74M
Volume:
2.37M
Avg Vol (2M):
3.49M
Also Trade In:
Volume:
2.37M
Market Cap $:
698.53M
PE Ratio:
At Loss
Avg Vol (2-Month):
3.49M
Enterprise Value $:
173.74M
PB Ratio:
1.15
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Nektar Therapeutics
NAICS : 325412 SIC : 2834
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Financials (Next Earnings Date:2022-08-05 Est.)

NKTR's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:NKTR

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 103.082
EPS (TTM) ($) -2.67
Beta 0.76
Volatility % 65.75
14-Day RSI 48.41
14-Day ATR ($) 0.276087
20-Day SMA ($) 3.6655
12-1 Month Momentum % -79.74
52-Week Range ($) 3.02 - 19.37
Shares Outstanding (Mil) 186.27

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Nektar Therapeutics Filings

Document Form Filing Date
No Filing Data

Headlines

See More